Stocks Health care APTN
OTC · Health careAdaptin Bio, Inc. (APTN)
It posted a net loss of $5.4M. At June 30, 2026 it held $670.5K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Adaptin Bio, Inc.
- Net worth
- Adaptin Bio, Inc. has a market value (market cap) of $57.9M at the latest share price, and shareholders' equity of -$1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $4.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Adaptin Bio, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Adaptin Bio, Inc. does
Adaptin Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker APTN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$5.2M | -$0.66 | n/a |
| 2024 | n/a | -$3.1M | -$0.96 | n/a |
| 2023 | n/a | -$85.6K | -$0.51 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Adaptin Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026IPO registration S-1
- August 25, 2026Other event 8-K
- August 13, 2026
- July 21, 2026Form POS AM filing POS AM
- June 12, 2026
- May 15, 2026
- April 6, 2026Other event 8-K
- April 1, 2026
- April 1, 2026Late annual report notice NT 10-K
- December 23, 2025
Insider trades
What the people running Adaptin Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns APTN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Michael J. Roberts13D, may seek influence | 26.7% | February 18, 2025 |
| Simon Pedder13D, may seek influence | 11.5% | February 18, 2025 |
Largest institutional holders
Insiders
Questions about APTN
What does Adaptin Bio, Inc. do?
Adaptin Bio, Inc. is a company in the Health care sector, listed on OTC as APTN. Its shares trade on OTC under the ticker APTN.
What is Adaptin Bio, Inc.'s net worth?
Adaptin Bio, Inc. has a market value (market cap) of $57.9M at the latest share price, and shareholders' equity of -$1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Adaptin Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.4M.
When did Adaptin Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from August 28, 2026.
When is Adaptin Bio, Inc.'s next earnings report?
Adaptin Bio, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare APTN with
Follow APTN
Get an email when Adaptin Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Adaptin Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.